Breaking: The FDA is now investigating internal complaints about Dr. Vinay Prasad,CBER director, with the help of an external investigator. $SRPT $MRNA $CRSP $EDIT $BEAM This is an extremely rare step. There is serious concerns about workplace issues at the agency! The move comes amid broader turmoil at the FDA, including criticism of Prasad’s leadership style and controversial decisions on drug and vaccine reviews - e.g. the recent Moderna’s flu shot or the non-ambulatory ban on Sarepta's Elevidys. If Prasad is pushed out, this will be extremely bullish names sensitive to regulatory tone, including: - $SRPT (Sarepta) - gene therapy pipeline - $MRNA (Moderna) - vaccine/therapeutic approvals - $CRSP (CRISPR Therapeutics) - gene editing assets - $EDIT (Editas Medicine) - FDA review path clarity - $BEAM (Beam Therapeutics) - precision editing programs Personally I think he will be gone in the next month - thoughts? https://t.co/ozEVcdKIz5

Surely Vinay Prasad has got to go! $MRNA $SRPT $NVO $CAPR https://t.co/prNAwP1TNg

$Moderna (https://t.co/u5HWDxrmlF)$ is on a roll, with investors hopeful that positive results from a cancer vaccine trial can revive the pharma stock after a stagnant.